PTIX — Protagenic Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00- $3.19m
- $4.47m
Annual cashflow statement for Protagenic Therapeutics, fiscal year end - March 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 March 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 8-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -4.52 | -3.56 | -5 | -5.53 | -3.59 |
| Depreciation | |||||
| Non-Cash Items | 1.86 | 1.02 | 1.38 | 0.791 | 1.48 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -0.14 | 0.54 | -0.114 | 0.468 | 0.348 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Payable / Accrued Expenses | |||||
| Cash from Operating Activities | -2.8 | -1.99 | -3.7 | -4.22 | -1.77 |
| Capital Expenditures | — | -0.002 | -0.15 | 0 | — |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | -9.91 | 1.6 | 4.93 | 2.8 | — |
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | -9.91 | 1.6 | 4.78 | 2.8 | — |
| Financing Cash Flow Items | 0 | — | — | — | — |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 12.6 | 0 | — | 1.96 | 1.81 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -0.13 | -0.326 | 1.07 | 0.551 | 0.013 |